Hope therapeutics™, inc. and nrx pharmaceuticals, inc. (nasdaq:nrxp) execute agreement for $27 million funding transaction for hope clinic acquisition

$25 million investment in hope to consist of series a (non-dilutive to nrx shareholders) convertible into 1/3 of fully diluted hope equity, with a 15% current preferred dividend (non-callable for 2 years) for planned hope clinic acquisitions initial funding of $2.0 million for purchase of nrx common stock anticipated to close on or before january 29, with the first tranche of $6.75 million of $25.0 million investment to be invested in hope therapeutics, inc. on or before february 7, 2025, and the balance of $18.25 million by april 1, 2025 funds will be used in conjunction with anticipated bank financing to initiate nationwide rollup strategy of interventional psychiatry clinics, starting with kadima neuropsychiatry (la jolla, ca) hope intends to initiate nationwide acquisition program in partnership with leading investment bank on or around february 1, 2025. miami , jan. 28, 2025 /prnewswire/ -- hope therapeutics™, inc. ("hope"), a medical and technology driven company, and a wholly-owned subsidiary of nrx pharmaceuticals, inc. ("nrx", and collectively with hope, the "company") (nasdaq:nrxp), today announced the signing and of a stock purchase agreement ("spa") with smith & sauer, llc, as the first step in a $27.0 million financing to fund the planned acquisition of hope clinics.
NRXP Ratings Summary
NRXP Quant Ranking